4551 — Torii Pharmaceutical Co Income Statement
0.000.00%
- ¥178bn
- ¥144bn
- ¥60bn
- 86
- 27
- 96
- 82
Annual income statement for Torii Pharmaceutical Co, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | — | JAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 41,700 | 46,987 | 48,896 | 54,638 | 60,426 |
| Cost of Revenue | |||||
| Gross Profit | 21,738 | 24,338 | 23,380 | 24,791 | 26,707 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 37,708 | 42,371 | 43,358 | 49,640 | 53,828 |
| Operating Profit | 3,992 | 4,616 | 5,538 | 4,998 | 6,598 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 4,225 | 4,767 | 5,722 | 5,593 | 6,725 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 3,496 | 3,375 | 3,944 | 4,120 | 5,043 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 3,496 | 3,375 | 3,944 | 4,120 | 5,043 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 3,495 | 3,374 | 3,944 | 4,119 | 5,042 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 146 | 121 | 140 | 148 | 185 |
| Dividends per Share |